These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 12871321

  • 21. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.
    J Thromb Haemost; 2005 Oct; 3(10):2211-8. PubMed ID: 16092924
    [Abstract] [Full Text] [Related]

  • 22. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
    Akinci B, Comlekci A, Ali Ozcan M, Demir T, Yener S, Demirkan F, Yuksel F, Yesil S.
    Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
    [Abstract] [Full Text] [Related]

  • 23. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 24. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission.
    Erdoğan M, Özbek M, Akbal E, Üreten K.
    Turk J Med Sci; 2019 Oct 24; 49(5):1381-1385. PubMed ID: 31549496
    [Abstract] [Full Text] [Related]

  • 25. Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population.
    Akatsu H, Ishiguro M, Ogawa N, Kanesaka T, Okada N, Yamamoto T, Campbell W, Okada H.
    Microbiol Immunol; 2007 Oct 24; 51(5):507-17. PubMed ID: 17579260
    [Abstract] [Full Text] [Related]

  • 26. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
    Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Miyata S, Kawamura T, Horiuchi H, Fukumoto Y, Shimokawa H.
    Arterioscler Thromb Vasc Biol; 2016 Jun 24; 36(6):1293-301. PubMed ID: 27102961
    [Abstract] [Full Text] [Related]

  • 27. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
    Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RG, Reitsma PH.
    J Thromb Haemost; 2004 Jan 24; 2(1):54-7. PubMed ID: 14717966
    [Abstract] [Full Text] [Related]

  • 28. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 29. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F, Carrieri C, Galasso R, Scaraggi FA, Di Serio F, Woodhams B, Semeraro N, Colucci M.
    J Thromb Haemost; 2013 Feb 01; 11(2):315-24. PubMed ID: 23256818
    [Abstract] [Full Text] [Related]

  • 30. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
    Koldas M, Gummus M, Seker M, Seval H, Hulya K, Dane F, Kural A, Gumus A, Salepci T, Turhal NS.
    Clin Lung Cancer; 2008 Mar 01; 9(2):112-5. PubMed ID: 18501098
    [Abstract] [Full Text] [Related]

  • 31. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
    Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I, Prime Study Group.
    J Thromb Haemost; 2005 Jul 01; 3(7):1503-10. PubMed ID: 15978108
    [Abstract] [Full Text] [Related]

  • 32. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC.
    Br J Haematol; 2004 Mar 01; 124(5):659-65. PubMed ID: 14871254
    [Abstract] [Full Text] [Related]

  • 33. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor.
    Bladbjerg EM, Skouby SO, Andersen LF, Jespersen J.
    Hum Reprod; 2002 Dec 01; 17(12):3235-41. PubMed ID: 12456630
    [Abstract] [Full Text] [Related]

  • 34. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP.
    Thromb Haemost; 2003 Jul 01; 90(1):92-100. PubMed ID: 12876631
    [Abstract] [Full Text] [Related]

  • 35. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
    Mook-Kanamori BB, Valls Serón M, Geldhoff M, Havik SR, van der Ende A, Baas F, van der Poll T, Meijers JC, P Morgan B, Brouwer MC, van de Beek D.
    J Thromb Haemost; 2015 Nov 01; 13(11):2076-86. PubMed ID: 26340319
    [Abstract] [Full Text] [Related]

  • 36. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD).
    Verdú J, Marco P, Benlloch S, Sanchez J, Lucas J.
    Thromb Haemost; 2006 Mar 01; 95(3):585-6. PubMed ID: 16525595
    [No Abstract] [Full Text] [Related]

  • 37. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 01; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 38. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
    Orikaza CM, Morelli VM, Matos MF, Lourenço DM.
    Thromb Res; 2014 Jan 01; 133(1):120-4. PubMed ID: 24252537
    [Abstract] [Full Text] [Related]

  • 39. A new functional assay of thrombin activatable fibrinolysis inhibitor.
    Guimarães AH, Bertina RM, Rijken DC.
    J Thromb Haemost; 2005 Jun 01; 3(6):1284-92. PubMed ID: 15946219
    [Abstract] [Full Text] [Related]

  • 40. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact.
    Frère C, Morange PE, Saut N, Tregouet DA, Grosley M, Beltran J, Juhan-Vague I, Alessi MC.
    Thromb Haemost; 2005 Aug 01; 94(2):373-9. PubMed ID: 16113828
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.